This article is more than 5 years old. Information may no longer be current.
PRIMA
Pro-Brain-Natriuretic Peptide-Guided Therapy of Chronic HF for Improvement of HF Morbidity and Mortality
Researchers tested whether management of HF guided by an individualized N-terminal pro–B-type natriuretic peptide (NT-proBNP) target would benefit outcome when compared with HF management guided by clinical assessment only.
Design: randomized, prospective, single blind
Patients: 345
Centers: multicenter
Countries: Netherlands
Results: Although individualized NT-proBNP target therapy increased HF medication use (P=.006) and advanced detection of HF-related events, it did not significantly improve the primary endpoint of number of days alive outside the hospital setting (P=.49). Patients experienced nonstatistically significant lower rates of mortality in the NT-proBNP arm (26.5% vs. 33.3%), but there were no differences between the total number of CV and HF-related admissions between groups.
Published in: J Am Coll Cardiol. 2010;56:2090-2100.
Read more about the PRIMA trial here.